Vertex Pharmaceuticals develops biotechnology medicines for serious diseases and conditions, with commercial franchises in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. Company news commonly covers CFTR modulators including ALYFTREK and TRIKAFTA, the CRISPR/Cas9 gene-edited therapy CASGEVY, and JOURNAVX, an oral non-opioid pain signal inhibitor.
Updates also track financial results, regulatory approvals and label expansions, reimbursement and patient-access agreements, clinical data presentations, and pipeline programs in kidney disease, neuropathic pain, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1. Vertex disclosures frequently connect revenue trends with progress across approved products and investigational programs such as povetacicept for IgA nephropathy.
Vertex Pharmaceuticals (NASDAQ: VRTX) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET. The event will include a live webcast accessible through the Vertex website in the 'Investors' section. Vertex is a biotechnology firm focused on developing transformative medicines, particularly for cystic fibrosis. The company has multiple approved therapies and a robust pipeline targeting other serious diseases, including sickle cell disease and type 1 diabetes. Founded in 1989, Vertex is headquartered in Boston.
Vertex Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for VX-522, a novel inhaled mRNA therapy for cystic fibrosis, targeting approximately 5,000 patients who cannot benefit from existing CFTR modulators. A clinical trial evaluating the safety of VX-522 is set to begin in the coming weeks. This breakthrough follows a collaboration with Moderna established in 2016, combining Vertex's expertise in cystic fibrosis and Moderna's mRNA technology to target the underlying cause of the disease.
Vertex Pharmaceuticals and CRISPR Therapeutics announced upcoming oral presentations of clinical data for exagamglogene autotemcel (exa-cel) at the 2022 ASH Annual Meeting. This investigational therapy targets sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Key presentations include efficacy and safety data from Phase 3 trials, with plans for regulatory submissions in the U.S., U.K., and EU by early 2023. The studies highlight the quality of life impacts for patients undergoing treatment.
Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of $224 million along with $26 million in equity and is eligible for future milestone payments totaling up to $485 million. The collaboration focuses on Entrada’s late-stage preclinical candidate, ENTR-701, which aims to address underlying causes of DM1. Vertex will lead further development, manufacturing, and commercialization efforts.
Vertex Pharmaceuticals (NASDAQ: VRTX) will participate in key investor conferences including the Jefferies London Healthcare Conference on November 16, 2022, at 9:10 a.m. GMT and the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:15 a.m. EST. Live webcasts of these events will be accessible on Vertex's website. Established in 1989, Vertex focuses on innovative treatments for serious diseases, particularly cystic fibrosis, and has a promising pipeline addressing various serious conditions. For more information, visit www.vrtx.com.
Vertex Pharmaceuticals (NASDAQ: VRTX) has partnered with basketball Hall-of-Famer Alonzo Mourning to launch the "Power Forward" initiative. This educational campaign aims to raise awareness about APOL1-mediated kidney disease (AMKD), emphasizing the significance of early diagnosis and genetic testing. AMKD affects approximately 100,000 individuals in the U.S. and is genetically driven, particularly impacting those of sub-Saharan African ancestry. The initiative offers resources to help at-risk individuals discuss kidney health with healthcare providers.
Vertex Pharmaceuticals (NASDAQ: VRTX) reports promising long-term data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor), showcased at the North American Cystic Fibrosis Conference. The ongoing 192-week study shows sustained improvements in lung function and respiratory symptoms among patients with at least one F508del allele. In children aged 2-5, TRIKAFTA improved lung function and was generally well-tolerated. Vertex plans to submit regulatory applications for this age group. The latest findings reinforce TRIKAFTA's critical role in CF treatment.
Vertex Pharmaceuticals reported Q3 2022 product revenues of $2.33 billion, marking an 18% increase from Q3 2021. The company raised its full-year 2022 product revenue guidance to $8.8 billion to $8.9 billion, driven by strong uptake of TRIKAFTA/KAFTRIO. Net income increased by 9% to $931 million, with a diluted EPS of $3.59. Vertex continues to advance its clinical pipeline, including exa-cel for Sickle Cell Disease and VX-548 for acute pain, while increasing R&D investments.
Vertex Pharmaceuticals (NASDAQ: VRTX) will report its Q3 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, accessible via phone and live webcast on Vertex's website.
Vertex is a leader in biotechnology, focusing on transformative medicines for serious diseases, particularly cystic fibrosis, and has a robust pipeline addressing other conditions like sickle cell disease and type 1 diabetes. The company is recognized as a top employer in the industry.
Vertex Pharmaceuticals (NASDAQ: VRTX) has initiated a first-in-human trial for VX-634, a new AAT corrector for alpha-1 antitrypsin deficiency (AATD). The FDA has approved the IND application for VX-634, marking a significant advancement in the company's AATD program. Alongside this, Vertex plans to launch a 48-week Phase 2 study of VX-864 to evaluate its long-term efficacy in reducing liver polymer levels and increasing functional AAT in plasma. The company will also introduce additional AAT correctors starting in 2023.